Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States
about
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian PerspectivePsoriasis causes significant economic burden to patients.The cost of biologics for psoriasis is increasingCost-of-illness in psoriasis: comparing inpatient and outpatient therapy.Health economic analyses of psoriasis management: a systematic literature search.Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines.Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.Psoriasis treatment and management - a systematic review of full economic evaluations.Systematic review of cost-effectiveness analyses of treatments for psoriasis.Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle.Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan.Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults.Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
P2860
Q26747639-D103186F-8230-4683-B69E-987B17471E0CQ33785034-70E72D64-9CE8-4C28-A588-FB4C5C3CBFC8Q34973745-F3FC493C-342A-4F77-AB60-AEFB4B4980FEQ35032509-45228888-1F90-491F-BD94-6FC47806667DQ36082201-ED1CD733-D074-44C2-AB27-D2D906CEF8C8Q37268868-8DED946E-A306-4DD5-8442-F1F06E389447Q37660470-7C2EF14B-0CCF-4BC9-83C0-ED031775A7D5Q38013239-503D8646-0DD9-4879-A6F6-06C6B513BF42Q38211315-92C45A5B-6B51-46FC-8D97-C04B4BC103C2Q38260967-26282A08-790C-4B7E-9F22-228C849B370CQ38283299-0C43CB2D-4AB1-4569-A6EB-00850199B976Q41957838-820097CE-BB3C-4B54-90A0-5B2D27800F27Q45972851-43496E50-7A34-4546-9C02-D3D1DC632582Q46945261-635DAC15-C7C1-409F-83BF-4D89888ED5CAQ47093829-032CF258-6DEE-493B-9389-A70F8EB6E54FQ47292115-4B747692-F77D-43C6-84B9-320419C8D31FQ52855161-094FBA72-2F76-4941-98D6-94B801E349D3
P2860
Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States
description
im Mai 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 05 May 2010
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2010
@uk
name
Economic evaluation of biologi ...... psoriasis in the United States
@en
Economic evaluation of biologi ...... psoriasis in the United States
@nl
type
label
Economic evaluation of biologi ...... psoriasis in the United States
@en
Economic evaluation of biologi ...... psoriasis in the United States
@nl
prefLabel
Economic evaluation of biologi ...... psoriasis in the United States
@en
Economic evaluation of biologi ...... psoriasis in the United States
@nl
P2093
P2860
P1476
Economic evaluation of biologi ...... psoriasis in the United States
@en
P2093
Aslam H Anis
Mary K Willian
Shiraz R Gupta
Sonia Sizto
P2860
P356
10.3109/09546630903551258
P577
2010-05-05T00:00:00Z